The global Active Pharmaceutical Ingredient Market size is set to gain impetus from the rising implementation of strict norms and regulations in several countries regarding the production of high-quality API. It is further aiding in upsurging the overhead costs of in-house API manufacturing. Therefore, numerous pharmaceutical companies are focusing on outsourcing the manufacturing.
This information is provided by Fortune Business Insights™ in a recent report, the report further mentions that the Active Pharmaceutical Ingredient Market size stood at USD 164.20 billion in 2018 and is projected to reach USD 261.28 billion by 2026, exhibiting a CAGR of 6.1% during the forecast period.
High Demand for Novel Drugs to Boost Growth
The Indian Brand Equity Foundation (IBEF) mentioned that during 2015 to 2020, the pharmaceutical industry of India is set to exhibit a considerable CAGR of 22.4%. As per one of our lead analysts, “The incidence of chronic diseases is surging at a fast pace worldwide backed by the rising geriatric population. Rapid urbanization, as well as increasing adoption of sedentary lifestyle would also contribute to the growth.”
Apart from that, there is an alarming rise in the number of new cases of chronic diseases. It is therefore, skyrocketing the demand for state-of-the-art drugs. High demand for biosimilars and biologics would hence, propel the active pharmaceutical ingredient Industry growth in the coming years. However, changes in price policies in the developing nations may hamper growth.
Presence of Many Contract Manufacturing Organizations to Favor Growth in Asia Pacific
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
In terms of region, the market is divided into Asia Pacific, Europe, Latin America, the Middle East and Africa, and North America. Amongst these, in 2018, North America procured USD 79.80 billion Active Pharmaceutical Ingredient Market revenue. This growth is attributable to the rising government initiatives to develop unique drugs, as well as the rising prevalence of chronic diseases in this region.
Asia Pacific, on the other hand, is expected to outpace Europe and North America in the near future because of the rising number of pharmaceutical industries and contract manufacturing organizations present in the developing countries, such as India and China. Owing to the availability of raw material in abundance and lower labour cost, these countries have started becoming major venues for outsourcing API manufacturing. Also, several manufacturers have implemented favourable regulatory policies in this region to broaden their production capacity. It would also boost growth.
Source: Globenews Wire
